On Thursday, Ladenburg Thalmann up to date its monetary outlook on United Therapeutics Corp . (NASDAQ:), elevating the value goal to $344 from the earlier $319, whereas sustaining a Impartial score on the inventory. This adjustment follows the discharge of the corporate’s third-quarter monetary outcomes for 2024.
United Therapeutics reported whole revenues of $748.9 million for the third quarter, a determine that barely surpassed Ladenburg’s estimate of $746.5 million. This income represents a notable improve from the $609.4 million recorded in the identical quarter of the earlier yr, primarily as a result of heightened gross sales of treprostinil-based merchandise.
Nevertheless, not all merchandise met the agency’s gross sales expectations. Remodulin gross sales reached $128.3 million, falling wanting each Ladenburg’s projection of $150.2 million and the consensus estimate of $140.4 million. Then again, Tyvaso gross sales exceeded expectations, with whole gross sales amounting to $433.8 million in opposition to Ladenburg’s forecast of $418.1 million and the consensus of $421.5 million. The Tyvaso Dry Powder Inhaler (DPI) was a big contributor to this determine, with gross sales of $274.6 million.
Orenitram gross sales additionally offered a combined consequence, with a reported $113.2 million in gross sales. This was under Ladenburg’s estimate of $114.6 million however exceeded the consensus estimate of $105.7 million. Moreover, Unituxin gross sales outperformed expectations, producing $61.1 million in comparison with Ladenburg’s estimate of $57.9 million and the consensus of $53.7 million. Gross sales of Adcirca had been reported at $7.0 million.
This text was generated with the assist of AI and reviewed by an editor. For extra data see our T&C.
